Experience of switching to NovoEight: views of people with haemophilia

Debra Pollard; Kate Khair; Mike Holland

doi:10.17225/jhp00157

Abstract

Abstract

Management of haemophilia A requires administration of factor VIII therapy which, for those with severe haemophilia A in the UK, is predominantly self-administered at home in a prophylactic regimen to prevent or minimise bleeding. The UK undertakes a national tendering process every three years to ensure access to current and new therapies at a cost-effective price, through contracting for large volumes from individual suppliers. This means that some products may no longer be available and that new products can enter the UK market at any tendering stage.

In the latest tendering round, in 2018, more than one product was withdrawn from the UK market and a new product (NovoEight^®; Novo Nordisk) was added to the prescribing list. This meant people with haemophilia having to change products. The experience of 77 people with haemophilia or their carers who changed treatment products during this process was captured by questionnaires administered by haemophilia nurses from 12 treatment centres. Overall, although people with haemophilia felt that they had little influence in decision making about changing to NovoEight, they were confident with their new treatment including packaging and accessories for administration. This was seen more in those who switched from plasma-derived products where ease of infusion was rated highly. Users’ views of haemophilia treatment should be collected at times of change to identify facilitators and barriers experienced in self-management

Article

View Full Article

References

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47. doi: https://doi.org/10.1111/j.1365-2516.2012.02909.x.
2. Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: https://doi.org/10.1111/hae.12169.
3. NovoEight^® Summary of Product Characteristics, April 2018. Available from https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf (accessed 27 April 2020).
4. Pollard D, Khair K, Holland M. Switching factor products: nurses’ experience with NovoEight. J Haem Pract 2020; 7(1): 59–69. doi: https://doi.org/10.17225/jhp00156.
5. Chaugule SS, Hay JW, Young G. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence 2015; 9:1623–30. doi: https://doi.org/10.2147/PPA.S92985.
6. Remor E. Predictors of treatment difficulties and satisfaction with haemophilia therapy in adult patients. Haemophilia 2011; 17(5): e901–5. doi: https://doi.org/10.1111/j.1365-2516.2011.02578.x.
7. Cimino E, Linari S, Malerba M, Halimeh S, Biondo F, Westfeld M. Patient preference and ease of use for different coagulation factor VIII reconstitution device scenarios: a cross-sectional survey in five European countries. Patient Prefer Adherence 2014; 8: 1713–20. doi: https://doi.org/10.2147/PPA.S64709.
8. Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of MixPro^® among users and nurses. J Haem Pract 2017; 5(1): 12–23. doi: https://doi.org/10.17225/jhp00106.
9. Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19(5): 698–705. doi: https://doi.org/10.1111/hae.12165.
10. Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19(5): 691–7. doi: https://doi.org/10.1111/hae.12159.
11. Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial. Haemophilia 2018; 24(6): e391–e394. doi: https://doi.org/10.1111/hae.13617.
12. Brand-Staufer B, Dahl PW, Johansen SD, Nohr AM. Turoctocog alfa is stable during storage at 40°C and multiple sequences of temperature cycling. Presented at WFH 2018 World Congress, Glasgow, UK, 21 May 2018.
13. Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence 2018; 12: 431–41. doi: https://doi.org/10.2147/PPA.S151812.
14. Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med 2017; 8: 67–73. doi: https://doi.org/10.2147/JBM.S103796.

PDF Download

Download PDF

Open in full-page viewer

Authors

Debra Pollard

Debra.Pollard@nhs.net

Katharine Dormandy Haemophilia & Thrombosis Centre, Royal Free Hospital, London, UK .
Kate Khair
Mike Holland

Haemnet, London, UK